PEAR-TREE

Indication: Localised Kidney Cancer

Location: United Kingdom (see below for sites)

Type: Observational

Trial Registration on ISRCTN

Background:

Kidney cancer is a significant area of unmet need. At the moment, localised kidney cancer can be treated by surgery, but advanced or metastatic cancer is often treated with a combination of drugs, including immunotherapy and targeted drugs.

The Pear platform is designed to see which drugs might work best for different tumours. PEAR-TREE is an early study that helps us optimise the doses of drugs involved.

Description:

This observational study is recruiting up to 20 patients who are undergoing surgery for kidney cancer. Patients are asked to donate 40ml of blood, and we use spare tumour from the time of surgery, which would otherwise be disposed of.

The goal of the study is to establish the best dose of drugs to test in the Pear system, and test their mechanism of action.

Protocol: Please see the protocol here. Active sites should use the most recent version

If you are interested in enrolling, please contact your doctor about whether you are eligible.

For more information, contact trials@pearbio.com

Open Sites & Investigators:

This study is only open at the Royal Free Hospital, London. The Chief Investigator is Prof. Maxine Tran